{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:24:28Z","timestamp":1791379468990,"version":"4.3.3"},"reference-count":20,"publisher":"MedWorks Media","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>~ Alzheimer\u2019s disease (AD) is a devastating relentlessly progressive illness for which currently there is no definitive curative treatment. The mainstay of treatment remains symptomatic, though. Psychopharmacotherapy is only part of a multi-pronged package of care involving caregivers. Herein, authors would shed light on the main pharmacological options at hand.<\/jats:p>","DOI":"10.64719\/pb.16605","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:16:27Z","timestamp":1773260187000},"page":"170-175","source":"Crossref","is-referenced-by-count":0,"title":["Psychopharmacotherapy of Alzheimer\u2019s Disease\u2014What Do We Have at Hand?"],"prefix":"10.64719","volume":"56","author":[{"given":"Ahmed","family":"Naguy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saxby","family":"Pridmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anubhuti","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awadhesh","family":"Solanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Schneider LS. Alzheimer\u2019s and dementia guidelines and tables. Psychopharmacol Bull. 2023;53(2):8\u201365.","DOI":"10.64719\/pb.4463"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Naguy A. Transdermal psychotropic agents: \u2018Aye\u2019 or \u2018Nay\u2019? Prim Care Companion CNS Disord. 2021;23(2) 20br02673.","DOI":"10.4088\/PCC.20br02673"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Friedli MJ, Inestrosa NC. Huperzine A and its neuroprotective molecular signaling in Alzheimer\u2019s disease. Molecules. 2021;26(21):6531.","DOI":"10.3390\/molecules26216531"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Aljuwaiser M, Alayadhi N, Ozidu V et al. Clinical Indications of memantine in psychiatry-science or art? Psychopharmacol Bull. 2023;53(1):30\u201338.","DOI":"10.64719\/pb.4459"},{"key":"ref5","unstructured":"Lanctot KL, Herrmann N, Yau KK et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer\u2019s disease: a meta-analysis. CMAJ. 2003;169(6):557\u2013564."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Calsolaro V, Femminella GD, Rogani S et al. Behavioral and psychological symptoms in dementia (BPSD) and the use of antipsychotics. Pharmaceuticals (Basel). 2021;14(3):246.","DOI":"10.3390\/ph14030246"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Naguy A, Pridmore S, Abuzeid MY et al. Antipsychotics-therapeutic salve or iatrogenic thorn? Psychopharmacol Bull. 2025;55(4):1\u20137.","DOI":"10.64719\/pb.4513"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Lee D, Slomkowski M, Hefting N et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial. JAMA Neurol. 2023;80(12):1307\u20131316.","DOI":"10.1001\/jamaneurol.2023.3810"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Alawadi S, Naguy A. Cannabis for psychiatric disorders \u2013 Has the pendulum swung too far? Asian J Psychiatr. 2022;69:102995.","DOI":"10.1016\/j.ajp.2021.102995"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Naguy A, Alkhadhari S. Geriatric depression: what clinicians need to know? Prim Care Companion CNS Disord. 2024;26(3):23lr03686.","DOI":"10.4088\/PCC.23lr03686"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Naguy A, Alablani D, Alsalem NJ et al. Psychopharmacology of apathy. Am J Ther. 2025;32(4):e354\u2013e355. doi: 10.1097\/MJT.0000000000001860.","DOI":"10.1097\/MJT.0000000000001860"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Naguy A, Alamiri B, Shoukry T. Melatonin use in psychiatry-quo vadis? Am J Ther. 2020;27(5):e495\u2013e499.","DOI":"10.1097\/MJT.0000000000000833"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Naguy A, Pridmore S, Alamiri B. Newly FDA-approved psychotropic medications. Asian J Psychiatr. 2022;77:103275.","DOI":"10.1016\/j.ajp.2022.103275"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Naguy A, Alayadhi N, Pridmore S et al. FDA-approved psychotropic medications. Asian J Psychiatr. 2023;2023;87:103684.","DOI":"10.1016\/j.ajp.2023.103684"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Naguy A, Alayadhi N, AlTajali A et al. FDA-approved psychotropic medications: a conspectus. Asian J Psychiatr. 2024;2024;102:104249.","DOI":"10.1016\/j.ajp.2024.104249"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Pagotto GLO, Des Santos LMO, Osman N, et al. Ginkgo biloba: a leaf of hope in the fight against Alzheimer\u2019s dementia: clinical trial systematic review. Antioxidants (Basel). 2024;13(6):651.","DOI":"10.3390\/antiox13060651"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Zhao R, Han X, Zhang H et al. Association of vitamin E intake in diet and supplements with risk of dementia: a meta-analysis. Front Aging Neurosci. 2022;14:955878.","DOI":"10.3389\/fnagi.2022.955878"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Naguy A, Alamiri B. Lithium beyond bipolar mood disorders: a hope or hype? Prim Care companion CNS Disord. 2022;24(5) 21br03109.","DOI":"10.4088\/PCC.21br03109"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Bohnen JL, Albin RL, Bohnen NI. Ketogenic interventions in mild cognitive impairment, Alzheimer\u2019s disease, and Parkinson\u2019s disease: a systematic review and critical appraisal. Front Neurol. 2023;14:1123290.","DOI":"10.3389\/fneur.2023.1123290"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Chakkera M, Ravi N, Ramaraju R et al. The efficacy of vitamin d supplementation in patients with Alzheimer\u2019s disease in preventing cognitive decline: a systematic review. Cureus. 2022;14(11):e31710.","DOI":"10.7759\/cureus.31710"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:36:54Z","timestamp":1791315414000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/psychopharmacotherapy-of-alzheimers-disease-what-do-we-have-at-hand\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.16605","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}